Corbus Pharmaceuticals Holdings, Inc. CRBP
Regular-session close
After hours · Nov 16, 4:25 PM ET
- YTD
- -58.54%
- 1 year
- -69.51%
- Market cap
- 69.55M
- EPS (ttm)
- -6.04
- Shares out
- 12.18M
- Forward P/E
- -2.51
- YTD return
- -58.54%
- 1-year return
- -69.51%
- 50-day average
- 16.87
- 200-day average
- 37.65
- Enterprise value
- 2.58M
- Volume
- 953.48K
- Avg volume
- 1.08M
- Open
- 3.41
- Previous close
- 3.39
- Day's range
- 3.00 – 3.62
- 52-week range
- 2.86 – 12.15
- Beta
- 2.56
- Analysts
- Strong Buy
- Price target
- 56.78 (+1582.3%)
5D +0.34 (+11.45%)
Key statistics
- Price / book
- 1.06
- Free cash flow
- -25.40M
- Total cash
- 159.36M
- Total debt
- 3.61M
- Return on equity
- -51.32%
- Short % of float
- 24.72%
Fundamental scorecard
4 of 25 checks passed on CRBP’s reported financials
4of 25 checks passed
- Value 1 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.99 | -1.15 | -0.16 | -16.16% |
| Aug 6, 2024 | Jun 1, 2024 | -1.16 | -0.90 | +0.26 | +22.41% |
| May 7, 2024 | Mar 1, 2024 | -1.09 | -0.83 | +0.26 | +23.85% |
| Mar 12, 2024 | Dec 1, 2023 | -2.36 | -1.81 | +0.55 | +23.31% |
| Nov 7, 2023 | Sep 1, 2023 | -2.06 | -2.27 | -0.21 | -10.19% |
| Aug 8, 2023 | Jun 1, 2023 | -3.10 | -2.05 | +1.05 | +33.87% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 2, 2024 | Piper Sandler | init | — | Overweight |
| Aug 7, 2024 | RBC Capital | reit | Outperform | Outperform |
| Aug 7, 2024 | Oppenheimer | main | Outperform | Outperform |
| Aug 6, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 10, 2024 | Oppenheimer | reit | Outperform | Outperform |
| Jun 26, 2024 | B. Riley Securities | init | — | Buy |
About Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- corbuspharma.com
News
Biotech ETFs Brace for FDA Showdown: Two Drug Decisions Could Test Investor Sentiment
Corbus Pharmaceuticals presents Phase 1b CANYON-1 clinical trial data for CRB-913 at ObesityWeek® 2026 Mizuho Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $23
RBC Capital Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $33
Wedbush Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $27
Corbus Pharmaceuticals Q3 EPS $(1.81) Misses $(1.20) Estimate
Corbus Pharmaceuticals Reports Q3 2026 Financial Results and Provides a Corporate Update
Corbus Pharmaceuticals Launches Phase 3 Cancer Trial, Teases More Obesity Drug Data Corbus Pharmaceuticals To Present Late Breaking Data From CRB-913 Canyon-1 Phase 1B Study At Obesity Week 2026
Your note
Sign in to keep a note on CRBP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALTMEYER ANNE | Director | Stock Award(Grant) | May 29, 2024 | 2,783 |
| CATLIN AVERY W | Director | Stock Award(Grant) | May 29, 2024 | 4,350 |
| COHEN YUVAL | Chief Executive Officer | Sale | Jun 17, 2024 | 77,221 |
| CORMORANT ASSET MANAGEMENT ,L.P | Beneficial Owner of more than 10% of a Class of Security | Purchase | Sep 19, 2024 | 0 |
| HOLMER ALAN F | Director | Conversion of Exercise of derivative security | Jun 13, 2024 | 5,829 |
| JACQUES RACHELLE SUZANNE | Director | Stock Award(Grant) | May 29, 2024 | 2,783 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Cormorant Asset Management, LP | 19.50% | 2,375,000 | 31.25M | Sep 29, 2024 |
| Octagon Capital Advisors LP | 9.15% | 1,115,000 | 14.67M | Sep 29, 2024 |
| Orbimed Advisors LLC. | 7.49% | 912,552 | 12.01M | Sep 29, 2024 |
| Blackrock Inc. | 6.59% | 802,721 | 10.56M | Sep 29, 2024 |
| Vanguard Group Inc | 5.30% | 645,650 | 8.50M | Sep 29, 2024 |
| Tang Capital Management, LLC | 4.93% | 600,000 | 7.90M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 3.21% | 391,276 | 5.15M | Sep 29, 2024 |
| Vanguard Total Stock Market Index Fund | 2.70% | 329,220 | 4.33M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.21% | 269,243 | 3.54M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.39% | 169,055 | 2.22M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.85% | 104,055 | 1.37M | Aug 30, 2024 |
| Fidelity Extended Market Index Fund | 0.56% | 68,254 | 898.22K | Oct 30, 2024 |
